Coagulation factor VIII gene (F8) (F8)

The Coagulation factor VIII gene (F8) is located on the X chromosome and provides instructions for making the Factor VIII protein, an essential cofactor in the blood clotting cascade. Mutations in the F8 gene result in Hemophilia A, a genetic disorder where blood does not clot properly, leading to spontaneous or prolonged bleeding episodes (NCBI Gene ID: 2157). As a target for genomic integration or correction, the F8 gene is the focus of gene therapies designed to provide a functional copy of the gene or repair existing mutations within the patient's genome (PubMed: 31067375). Therapeutic strategies often involve adeno-associated virus (AAV) vectors to deliver the F8 transgene to hepatocytes, the primary site of Factor VIII production. Emerging gene editing technologies like CRISPR/Cas9 are also being explored to achieve precise correction of F8 mutations at the endogenous locus, potentially offering a permanent cure (PubMed: 30635557). Monitoring Factor VIII activity levels and the development of neutralizing antibodies, known as inhibitors, are critical for assessing the efficacy and safety of these interventions. Safety considerations include the risk of insertional mutagenesis and the potential for an immune response against the viral vector or the newly synthesized Factor VIII protein. Successful genomic integration aims to achieve stable, long-term expression of Factor VIII to eliminate the need for frequent prophylactic protein infusions.

Other names

Factor VIII geneF8CHEMAFVIII geneAntihemophilic factor gene

Gene addition or site-specific genomic correction to restore functional Factor VIII protein production.